MetaVia Inc., a clinical-stage biotechnology company, announced its financial results for the second quarter ended June 30, 2025. The company reported a net loss of $4.0 million, compared to a net loss of $10.1 million in the same period in 2024. For the six months ended June 30, 2025, the net loss was approximately $7.7 million, a reduction from the approximately $16.8 million loss for the same period in 2024. Operating expenses for the six months ended June 30, 2025, were approximately $8.2 million, down from $17.0 million in the same period the previous year, primarily due to decreased R&D and general administrative expenses. Total other income increased to approximately $0.3 million for the second quarter of 2025, up from $31 thousand in the second quarter of 2024, mainly due to changes in the fair value of warrant liabilities. Cash holdings were reported at $17.6 million as of June 30, 2025, an increase from $16.0 million at the end of 2024, with expectations that this cash position will be adequate to fund operations into 2026. MetaVia also highlighted significant business developments, including dosing the first patient in an eight-week clinical trial for DA-1726 aimed at obesity treatment, with top-line data expected in the fourth quarter of 2025, and a new collaboration with Syntekabio to explore additional indications for DA-1241.